Placebo to match LY3527723, Placebo to match LY3527723, SELPERCATINIB, SELPERCATINIB
J2G-MC-JZJX
Phase 3 small_molecule active
Quick answer
Placebo to match LY3527723, Placebo to match LY3527723, SELPERCATINIB, SELPERCATINIB for RET fusion-Positive NSCLC is a Phase 3 program (small_molecule) at Eli Lilly Co. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Eli Lilly Co.
- Indication
- RET fusion-Positive NSCLC
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active